I hereby certify that this correspondence is being transmitted via Electronic Filing System to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on October 6, 2006

PATENT

Oksana Buynitzky Date of Signature

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Gonda et al.

Group Art Unit: Not Assigned

Serial No.: 10/550,533

Examiner: Not Assigned

Filed: September 23, 2005

Docket No.: 1386/21

For: METHOD FOR IDENTIFYING NUCLEIC ACID MOLECULES ASSOCIATED

WITH ANGIOGENESIS

SECOND SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

In accordance with 37 C.F.R. 1.56, 1.97, and 1.98, applicants' undersigned attorney brings to the attention of the Patent and Trademark Office the references listed on the attached form PTO-1449. Copies of the references A-AF as well as Form PTO-1449 are attached hereto as electronic files in PDF format.

This is not to be construed as a representation that a search has been made or that a reference is relevant merely because cited.

Early passage of the subject application to issue is earnestly solicited.

Atty. Docket No.: 1386/21

The Commissioner is hereby authorized to charge any fees associated with the filing of this correspondence to Deposit Account No. <u>50-0426</u>.

Respectfully submitted,

JENKINS, WILSON, TAYLOR & HUNT, P.A.

Date: October 6, 2006 By:

Arles A. Taylor, Jr.

Registration No. 39,395

Customer No.: 52354

1386/21 AAT/JD/omb

Enclosures

FORM PTO-1449 U.S. Department of Commerce	Application No.:	10/550,533
Patent and Trademark Office List of Documents Cited by Applicant	Filing Date:	September 23, 2005
	First Named Inventor:	Gonda Thomas John
	Group:	TBA
	Examiner:	TBA
Page 1 of 4	Attorney Docket No.:	1386/21

		V.	U.S. PATENT DO	DCUMENTS		
Examin er Initials	Cite No.	Document Number	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, where relevan passages or relevant figures appear	
		<u> </u>				÷
		FC	REIGN PATENT	DOCUMENTS		4
Examin er Initials	Cite No.	Document Number (country code, no., kind code (if known)	Publication Date	Name of Patentee or Applicant	Pages, columns, lines where relevant passages appear	Т
	А	EP 1293569	03/19/2003	Helix Research Institute; Research Association for Biotechnology		
	В	WO 00/55633	09/21/2000	EOS Biotechnology, Inc.		
	С	WO 00/58495	10/05/2000	Human Genome Sciences, Inc.		÷
	D	WO 00/73509	12/07/2000	Incyte Genomics, Inc.		
	E	WO 01/07611	02/01/2001	GENENTECH, Inc.		
	F	WO 01/11086	02/15/2001	EOS Biotechnology, Inc.		

EXAMINER	DATE CONSIDERED	

^{*}Examiner Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 U.S. Department of Commerce	Application No.:	10/550,533
Patent and Trademark Office	Filing Date:	September 23, 2005
List of Documents Cited by Applicant	First Named Inventor:	Gonda Thomas John
	Group:	ТВА
	Examiner:	ТВА
Page 2 of 4	Attorney Docket No.:	1386/21

	G	WO 01/60860	08/23/2001	Millennium Predictive Medicine, Inc.	,
	Н	WO 01/73027	10/04/2001	CORIXA CORPORATION	
	ļ	WO 01/96388	12/20/2001	CORIXA CORPORATION	
antidandrouwak com Makik in Arce Pataret Fraide	J	WO 02/08288	01/31/2002	GENENTECH, Inc.	
	к	WO 02/098358	12/12/2002	EOS Biotechnology, Inc.	
The state of the s	L	WO 02/102235	12/27/2002	EOS Biotechnology, Inc.	
	М	WO 02/29103	04/11/2002	GENE LOGIC, Inc.	
	N	WO 03/000296	01/03/2003	ISIS Innovations Limited	
	0	WO 03/000727	01/03/2003	ISIS Innovations Limited	
	Р	WO 03/003906	01/16/2003	EOS Biotechnology, Inc.	: :
And the second s	Q	WO 03/029273	04/10/2003	Whitehead Institute for Biomedical Research, Inc.	
	R	WO 03/083140	10/09/2003	St. Jude Children's Research Hospital, Inc.	
	s	WO 03/088910	10/30/2003	Rigel Pharmaceuticals, Inc.	
	Y	WO 04/007762	01/22/2004	Novartis Pharma GMBH	,
	U	WO 04/020591	03/11/2004	Five Prime Therapeutics, Inc.	

EXAMINER	DATE CONSIDERED	

^{*}Examiner Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 U.S. Department of Commerce	Application No.:	10/550,533
Patent and Trademark Office	Filing Date:	September 23, 2005
List of Documents Cited by Applicant	First Named Inventor:	Gonda Thomas John
	Group:	TBA
	Examiner:	TBA
Page 3 of 4	Attorney Docket No.:	1386/21

V	WO 04/020595	03/11/2004	Five Prime Therapeutics, Inc.; RIKEN The Institute of Physical and Chemical Research; Kabushiki Kaisha DNAFORM	
W	WO 04/039943	05/13/2004	CHIRON CORPORATION	
Х	WO 04/059001	07/15/2004	HENKEL KOMMANDITGESELLSC HAFT AUF AKTIEN	
 Y	WO 04/067778	08/12/2004	University of South Florida	
Z	WO 05/002414	01/13/2005	MOR Research Applications Limited	
AA	WO 05/005597	01/20/2005	Five Prime Therapeutics, Inc.; RIKEN The Institute of Physical and Chemical Research; Kabushiki Kaisha DNAFORM	
АВ	WO 05/011619	02/10/2005	Five Prime Therapeutics, Inc.	
AC	WO 05/014854	02/17/2005	Licentia, Ltd.	*
AD	WO 05/016962	02/24/2005	GENENTECH, INC.	
AE	WO 05/019258	03/03/2005	GENENTECH, INC.	• .
AF	WO 86/03838	07/03/1986	ONCOGEN	

OTHER DOCUMENTS

EXAMINER	DATE CONSIDERED	

^{*}Examiner Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 U.S. Department of Commerce	Application No.:	10/550,533
Patent and Trademark Office	Filing Date:	September 23, 2005
	First Named Inventor:	Gonda Thomas John
List of Documents Cited by Applicant	Group:	TBA
	Examiner:	TBA
Page 4 of 4	Attorney Docket No.:	1386/21

Examin er Initials	Cite No.	Include Author (in CAPITAL LETTERS), Title, Journal, Date, Pertinent Pages, Etc.	T
			,

EXAMINER	DATE CONSIDERED	

^{*}Examiner Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.